United States: FDA Marketing Exclusivity Periods Limited To Same Active Moiety

In Otsuka Pharm. Co., Ltd. v. Price, No. 16-5229 (D.C. Cir. Aug. 29, 2017), the U.S. Court of Appeals for the District of Columbia Circuit affirmed the district court decision upholding FDA's "same moiety" test for defining the zone of FDA market exclusivity periods. The case originated from Otsuka's Citizen's Petition asserting that FDA had improperly approved Alkermes's Section 505(b)(2) application for Aristada® (aripiprazole lauroxil) before expiration of the exclusivity periods for Otsuka's Abilify Maintena® (aripiprazole) product.

FDA Marketing Exclusivity Periods

The FFDCA provides three categories of drug applications that enjoy different FDA marketing exclusivity periods:

  1. Applications for drug products that contain "new chemical entities," i.e., for which "no active ingredient (including any ester or salt of the active ingredient) . . . has been approved in any other application." (Also known as "five-year NCE exclusivity.") See 21 USC § 355(c)(3)(E)(ii) ("romanette ii ).
  2. Applications for drug products that contain a previously approved active ingredient (including any ester or salt of the active ingredient) where "reports of new clinical investigations" are included. See 21 USC § 355(c)(3)(E)(iii) ("romanette iii").
  3. Applications that "supplement" a previously approved application, if obtaining approval of the supplement requires submitting additional clinical data. See 21 USC § 355(c)(3)(E)(iv) ("romanette iv").

Romanette ii confers five years of market exclusivity during which "no [abbreviated] application which refers to the [first-in-time] drug" may be approved. See 21 CFR § 314.3(b).

Romanette iii confers three years of exclusivity and bars approval of abbreviated applications for the same "conditions of approval of such drug in the [first-in-time] application." See 21 USC § 355(c)(3)(E)(iii).

Romanette iv confers three years of exclusivity and bars approval of abbreviated applications "for a change approved in the supplement" to the first-in-time drug's application. See 21 USC § 355(c)(3)(E)(iv).

The principal issue in this case involves delineating the scope of second-in-time applications that are barred by the romanette iii and romanette iv exclusivity periods.

Abilify Maintena® versus Aristada®

The first-in-time drug at issue was Otsuka's Abilify Maintena® ("AM") product, an extended release injectable suspension containing aripiprazole as the active moiety and active ingredient. (Otsuka's original orally administered Abilify® product included the same active moiety and active ingredient, and was accorded five-year NCE exclusivity.) In 2013, AM received three-year romanette iii exclusivity because its application relied on "new clinical investigations" to establish safety and efficacy. In 2014, Otsuka received approval for a supplemental NDA for AM when it submitted "the results of a controlled clinical study treating adult patients with schizophrenia experiencing an acute relapse." In view of this approval, it received three-year romanette iv exclusivity, in addition to the previously awarded romanette iii exclusivity.

Alkermes filed a Section 505(b)(2) application for Aristada® (aripiprazole lauroxil) for the treatment of schizophrenia. Like AM, Aristada® is an extended release injectable suspension, but Aristada® contains a different active ingredient–aripiprazole lauroxil instead of aripiprazole. As explained in the court's decision, aripiprazole lauroxil is metabolized into N-hydroxymethyl aripiprazole ("NHA"), which is the active moiety of Aristada®, and NHA in turn ultimately metabolizes into aripiprazole. As summarized by the court, to establish safety and efficacy of Aristada®, Alkermes relied partly on Otsuka's clinical investigations for Abilify® (but not those conducted for AM) and also conducted its own clinical investigations for Aristada®.

FDA's Same Moiety Ruling

In its Citizen's Petition, Otsuka contended that the Aristida® application fell within the scope of the romanettes iii and iv exclusivity periods for AM, because of overlapping "conditions of approval," given that Aristida® treated the same condition in a similar way despite having a structurally different active ingredient and active moiety.

FDA rejected Otsuka's arguments, finding that the exclusivity provisions did not bar approval of products that contain different active moieties. FDA explained that the exclusivity periods apply to a particular feature of the drug–the active moiety. As summarized in the court decision, FDA cited language in the eligibility clauses of romanettes ii, iii, and iv that conditions eligibility for exclusivity on whether a drug's "'active ingredient (including ester or salt of the active ingredient)' – i.e., its active moiety – has been approved in a previous application." FDA interpreted the term "such drug" in the bar clause of romanette iii as referring to the drug containing the active moiety of the first-in-time application, as defined in the eligibility clause. Applying the same rationale, the FDA concluded that under romanette iv, the "change approved in the supplement" must be for the same drug, i.e., containing the same active moiety, as in the supplemented application.

The Court Decisions

Otsuka sought judicial review of FDA's decision, and the district court granted summary judgment in favor of FDA and Alkermes. The district court determined that the FFDCA's three-year exclusivity bars only subsequent applications for drugs with the same active moiety, and concluded that FDA's same active moiety test is a reasonable construction of the FFDCA, is consistent with FDA's own regulations, and did not involve de facto rule making requiring a notice and comment period prior to implementation.

On appeal, the Court of Appeals for the D.C. Circuit agreed with FDA's rationale and affirmed the district court's decision. The court rejected Otsuka's argument that FDA's same moiety interpretation is inconsistent with the statute and the regulations. Applying the Chevron framework for APA challenges, the court accorded deference to FDA's interpretation because it was found to be consistent with the statute and regulations and to be reasonable.

With regard to when the exclusivity applies, the court adopted FDA's interpretation that for the exclusivity to apply, the subsequent application not only must share overlapping "conditions of approval," but also must be for the same drug as the first-in-time application. With regard to when a subsequent drug is considered to be the "same" as the first-in-time drug, the court found FDA's interpretation to be reasonable. FDA

Otsuka presented arguments based on a principle of legal equivalence in which two drugs should be considered legally equivalent if:

  • they have the same active moiety;
  • one drug relies on the other for FDA approval; or
  • one drug relies on a drug that is itself legally equivalent to the other drug.

Under this test, Aristada® would be legally equivalent to AM because the Aristada® application relied on Abilify® clinical studies and Abilify® and AM have the same active moiety.

However, the court rejected Otsuka's arguments because Otsuka had not shown why the FDA's interpretation is unreasonable. The court also found that Otsuka's interpretation would lead to much broader exclusivity than Congress intended, such as when a Section 505 (b)(2) applications relies on academic literature to establish safety and efficacy. The court also determined that Otsuka's legal equivalence test is inconsistent with the court's prior decision in Actavis Elizabeth LLC v. FDA, 625 F.3d 760 (D.C. Cir. 2010), where the court upheld FDA's endorsement of granting new chemical entity exclusivity to a prodrug of a previously approved drug, if it has a different active moiety.

The court also rejected Otsuka's arguments that the requirement that the Aristada® application contain patent certifications pertaining to Otsuka's aripiprazole method of use patents created legal equivalence. On this issue, the court cited different language in the different statutory provisions at issue, noting that "such drug" in the patent certification provision refers solely to the relied-upon drug, not both relied-upon and applied-for drugs.

Thus, the court affirmed FDA's decision that the three-year exclusivity periods only bar approval of subsequent applications when the drug at issue contains the same active moiety.

Impact Prodrug Litigation

The court's decision to uphold FDA's "same moiety" interpretation rationale is rooted in FDA's definition of "active moiety," which excludes ester derivatives and other non-covalent complexes. Thus, the court decision here directly applies only to covalent derivatives such as NHA, the active moiety in Aristada®. Covalent derivatives are usually associated with unpredictably altered pharmacological activity as compared to their first-in-time parent compounds, but some ester ester prodrugs (for example) may exhibit unexpected changes in pharmacological activity. It will be interesting to see how FDA treats such ester prodrugs, and whether it finds that three-year marketing exclusivity applies under Otsuka.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.